SCHEMBL317764

SCHEMBL317764

O=C(O)c1cccc(I)c1N1C(=O)CCC1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 2/20 0.38
NAPRT Q6XQN6 1/20 0.37
TP53 P04637 1/20 0.36
KMT2A Q03164 4/20 0.36
MAPK1 P28482 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 1/20 0.34
NR4A1 P22736 1/20 0.34
NR4A2 P43354 1/20 0.34
NR4A3 Q92570 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
KEAP1 Q14145 1/20 0.34
MEN1 O00255 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL317655 0.80 ALB (0.49) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL1834310 0.79 CA12 (0.41) CA12CA1CA9ALDH1A1TP53
SCHEMBL15636976 0.78 ALDH1A1 (0.43) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL31530993 0.77 MAOB (0.40) CA12CA1CA9ALDH1A1TP53
SCHEMBL4901236 0.76 TLR9 (0.49) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL334907 0.76 CA12 (0.39) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL6006263 0.75 TSHR (0.56) ALDH1A1KMT2ATSHRL3MBTL1MEN1
SCHEMBL28755352 0.73 TLR9 (0.45) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL3678196 0.73 NPC1 (0.48) CA12CA1CA9ALDH1A1ALOX15
SCHEMBL9262225 0.72 GAA (0.55) CA12CA1CA9ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023389-B2 Compositions that target tumor-associated macrophages and methods of use therefor Sanford Burnham Prebys Medical Discovery Institute (US) 2024-07-02 US disclosed
US-20240131201-A1 COMPOSITIONS THAT TARGET TUMOR-ASSOCIATED MACROPHAGES AND METHODS OF USE THEREFOR Sanford Burnham Prebys Medical Discovery Institute 2024-04-25 US disclosed
US-11571484-B2 Compositions that target tumor-associated macrophages and methods of use therefor Sanford Burnham Prebys Medical Discovery Institute (US) 2023-02-07 US disclosed
US-20200268910-A1 COMPOSITIONS THAT TARGET TUMOR-ASSOCIATED MACROPHAGES AND METHODS OF USE THEREFOR Sanford Burnham Prebys Medical Discovery Institute 2020-08-27 US disclosed
EP-3687559-A2 COMPOSITIONS THAT TARGET TUMOR-ASSOCIATED MACROPHAGES AND METHODS OF USE THEREFOR Sanford Burnham Prebys Medical Discovery Institute (US) 2020-08-05 EP disclosed
EP-2903629-B1 ANTIBODY CONJUGATE FOR USE IN TREATING INFLAMMATORY BOWEL DISEASE PHILOGEN SPA (IT) 2019-07-10 EP disclosed
WO-2019067984-A2 COMPOSITIONS THAT TARGET TUMOR-ASSOCIATED MACROPHAGES AND METHODS OF USE THEREFOR Sanford Burnham Prebys Medical Discovery Institute (US) 2019-04-04 WO disclosed
US-10239939-B2 Anti-ED-A immunoconjugates for inflammatory bowel disease PHILOGEN S.P.A. (IT) 2019-03-26 US disclosed
US-20180044408-A1 ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE PHILOGEN SPA (IT) 2018-02-15 US disclosed
US-9695232-B2 Anti-ED-A immunoconjugates for inflammatory bowel disease PHILOGEN S.P.A. (IT) 2017-07-04 US disclosed
EP-2495563-A1 DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES Fujifilm RI Pharma Co., Ltd. (JP) 2012-09-05 EP disclosed
US-20120219500-A1 DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES FUJIFILM RI PHARMA CO., LTD. (JP) 2012-08-30 US disclosed
US-8093405-B2 Formation of 18F and 19F fluoroarenes bearing reactive functionalities UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2012-01-10 US disclosed
CN-102300842-A Radioiodination method 2011-12-28 CN disclosed
US-20110280803-A1 RADIOIODINATION METHOD GE HEALTHCARE UK LIMITED (GB) 2011-11-17 US disclosed
EP-2382185-A1 RADIOIODINATION METHOD GE Healthcare Limited (GB) 2011-11-02 EP disclosed
EP-2310362-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES University Of Newcastle-Upon Tyne (GB) 2011-04-20 EP disclosed
WO-2010086398-A1 RADIOIODINATION METHOD GE HEALTHCARE LIMITED (GB) 2010-08-05 WO disclosed
WO-2009138763-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2009-11-19 WO disclosed
US-20090286992-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110280803-A1 RADIOIODINATION METHOD TPO, SSTR5, DAO CA12 407/4885CA1 426/4885CA9 245/4885
US-20090286992-A1 FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES RARB, RARG, RARA CA12 316/4885CA1 638/4885CA9 1392/4885
US-20120219500-A1 DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES NISCH, CNDP2, MYADM CA12 1889/4885CA1 3891/4885CA9 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.